+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacovigilance Market by Type, Product Life Cycle, Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast to 2030- Product Image
Pharmacovigilance Market by Type, Product Life Cycle, Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast to 2030- Product Image
Sale

Pharmacovigilance Market by Type, Product Life Cycle, Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5306611
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pharmacovigilance Market grew from USD 10.24 billion in 2024 to USD 11.84 billion in 2025. It is expected to continue growing at a CAGR of 15.85%, reaching USD 24.76 billion by 2030.

Setting the Stage for Pharmacovigilance Innovation

The rapid evolution of pharmacovigilance underscores its pivotal role in safeguarding public health and driving industry innovation. As patient safety demands intensify and regulatory landscapes become more stringent, organizations must adopt a forward-looking perspective to navigate emerging challenges and opportunities. This introduction lays the groundwork for understanding why robust safety surveillance is no longer optional but foundational to sustainable growth.

Advancements in data analytics and real-world evidence have transformed traditional monitoring approaches into dynamic, predictive systems capable of identifying adverse events earlier and more accurately. At the same time, the complexity of global supply chains and cross-border regulatory variations demands cohesive strategies that align operational excellence with compliance imperatives.

This executive summary presents an integrated view of the critical shifts shaping pharmacovigilance, from technological breakthroughs to geopolitical pressures. It aims to equip decision-makers with actionable insights, setting the stage for strategic investments that enhance patient outcomes, mitigate risks, and foster market competitiveness.

Evolving Dynamics Reshaping Pharmacovigilance Practices

Pharmacovigilance has entered a transformative era where digital tools and interdisciplinary collaboration are redefining the standards of drug safety monitoring. Artificial intelligence and machine learning now enable sophisticated signal detection, detecting nuanced patterns in vast unstructured data sources that once eluded manual review. These capabilities not only accelerate adverse event identification but also refine causality assessments with greater precision.

Concurrently, regulatory bodies worldwide are harmonizing guidelines, encouraging proactive risk management systems and intensified post-marketing surveillance. This regulatory convergence is stimulating investment in advanced case data management platforms that unify reporting, analysis, and remediation workflows across geographies.

Moreover, the integration of electronic health record mining and cohort event monitoring is expanding the scope of real-world evidence, bridging the gap between clinical trials and actual patient experiences. These shifts collectively signal a new paradigm in which agility, transparency, and data-driven decision-making become the cornerstones of modern pharmacovigilance.

United States Tariffs 2025 and Implications for Global Supply Chains

The United States tariffs scheduled for 2025 are poised to exert significant pressure on pharmaceutical supply chains and service providers worldwide. Elevated import duties on critical active pharmaceutical ingredients and safety surveillance technologies are expected to drive up operational costs for manufacturers and contract research organizations alike.

In response, many stakeholders are recalibrating their supplier networks, exploring nearshore and onshore options to mitigate tariff exposure. This strategic reshuffling underscores the growing importance of resilient supply chains that can absorb geopolitical shocks without compromising pharmacovigilance capabilities.

Furthermore, the cost implications are catalyzing a renewed focus on process optimization and digital automation within adverse event reporting systems. By leveraging cloud-based platforms and advanced analytics, organizations aim to streamline risk evaluation and reporting workflows, ensuring compliance while counterbalancing tariff-induced budget constraints.

Unveiling Critical Market Segments Driving Growth

The pharmacovigilance market is meticulously segmented by type to capture the full spectrum of safety monitoring approaches, encompassing cohort event monitoring for longitudinal patient follow-up and electronic health record mining for real-time data extraction. Intensified adverse drug reaction reporting elevates signal detection responsiveness, whereas spontaneous reporting and its targeted variant enhance the granularity of safety profiles.

Lifecycle considerations further subdivide the market across pre-clinical through phase IV stages, each presenting distinct monitoring priorities. Early-phase trials emphasize thorough preceptive oversight, while late-stage surveillance focuses on post-approval safety signals. This phased lens ensures comprehensive coverage from molecule inception to widespread patient use.

Delivery modes range from fully in-house pharmacovigilance operations, offering direct control over processes, to outsourced partnerships that unlock specialized expertise and scalable infrastructure. This dichotomy highlights the trade-off between autonomy and access to advanced analytics and global reporting networks.

Process flow segmentation addresses the end-to-end journey of safety data, starting with case data management, where case logging and medical review converge with rigorous data analysis. The risk management system layer integrates risk evaluation and mitigation mechanisms designed to preempt and manage safety concerns. Signal detection completes the cycle by uniting adverse event analysis with logging and thorough review, closing the loop for continuous improvement.

Therapeutic area segmentation spans cardiovascular, infectious diseases, neurology, oncology, and respiratory domains, each demanding tailored surveillance strategies aligned with distinct adverse event profiles. Parallel to these clinical dimensions, end users including biotechnology firms, medical device manufacturers, and pharmaceutical companies drive demand for customized pharmacovigilance solutions that align with their unique regulatory and operational contexts.

Regional Nuances Steering Pharmacovigilance Expansion

The Americas region commands significant market activity, driven by robust regulatory frameworks and widespread adoption of digital pharmacovigilance platforms. High market maturity in North America is supported by strong public-private partnerships and innovative data integration initiatives, fostering a culture of continuous safety monitoring.

In Europe, the Middle East & Africa, regulatory harmonization through agencies such as the European Medicines Agency and emerging safety guidelines across Middle Eastern jurisdictions are catalyzing investment in unified reporting systems. This region’s diverse healthcare infrastructure presents both challenges and opportunities for scalable pharmacovigilance implementations.

Asia-Pacific is experiencing rapid expansion, fueled by growing pharmaceutical manufacturing capacities in countries such as China and India. Heightened regulatory scrutiny and increasing collaboration between local authorities and global corporations are accelerating the adoption of cloud-based signal detection tools and real-world evidence analytics, positioning the region as a key growth driver.

Leading Players Forging the Future of Safety Surveillance

Leading organizations in the pharmacovigilance arena are distinguishing themselves through strategic investments in next-generation safety surveillance technologies. Some companies are forging alliances with data analytics firms to integrate AI-driven signal detection into their core offerings, while others are expanding global footprints to support 24/7 adverse event reporting and regulatory compliance.

Innovation is central to competitive differentiation, with top players developing end-to-end platforms that seamlessly unify case data management, risk management, and signal detection. Their platforms support multi-channel data ingestion, advanced causality assessment algorithms, and configurable risk mitigation workflows tailored to specific therapeutic areas.

Strategic acquisitions and partnerships are further shaping the competitive landscape, as organizations seek to augment their service portfolios with specialized capabilities, from intensified adverse drug reaction reporting to advanced cohort monitoring networks. These alliances underscore a broader trend towards consolidation and interoperability, driving efficiency and expanding global reach.

Strategic Imperatives for Industry Trailblazers

To thrive in this evolving environment, organizations should prioritize the integration of AI and machine learning into their signal detection frameworks. Automated algorithms can sift through vast real-world and clinical data sets, surfacing critical insights with unprecedented speed and accuracy. Simultaneously, investing in cloud-native platforms can enhance scalability and resilience, ensuring uninterrupted compliance with global reporting mandates.

Harmonizing data flows across internal silos and external partners is equally crucial. Establishing standardized data dictionaries and interoperable APIs fosters seamless collaboration, reduces manual errors, and accelerates time-to-insight. This cohesive approach should be complemented by robust training programs that equip pharmacovigilance professionals with the skills to leverage advanced analytics tools effectively.

Moreover, proactive regulatory engagement is essential. Organizations must maintain open dialogues with authorities to anticipate guideline changes and co-create best practice frameworks. Building dedicated risk management committees that include cross-functional stakeholders can streamline decision-making and fortify organizational readiness for emerging safety challenges.

Robust Methodology Underpinning Market Insights

This analysis synthesizes insights drawn from a rigorous research methodology that combines primary and secondary sources. Expert interviews with pharmacovigilance leaders provided firsthand perspectives on emerging technologies and regulatory trends, while peer-reviewed journals and regulatory publications offered a foundation of validated, current data.

Secondary research included comprehensive reviews of publicly available annual reports, white papers, and conference proceedings to ensure a holistic view of market drivers and challenges. Data triangulation techniques were employed to reconcile information from diverse sources, enhancing reliability and depth of the findings.

Segmentation frameworks were developed through iterative validation with industry experts, ensuring that categories such as delivery mode, process flow, and therapeutic area reflect real-world operational structures. This robust approach underpins the credibility of the insights and supports evidence-based decision-making for stakeholders across the pharmacovigilance ecosystem.

Synthesizing Trends and Pathways Ahead

In summary, the pharmacovigilance landscape is undergoing rapid transformation driven by technological innovation, regulatory convergence, and geopolitical factors such as the 2025 U.S. tariffs. Segmented market analysis reveals nuanced demands across types of monitoring, product life cycle stages, delivery models, process flows, therapeutic areas, and end-user profiles.

Regional insights highlight differentiated growth trajectories in the Americas, Europe, Middle East & Africa, and Asia-Pacific, each shaped by distinct regulatory and infrastructural dynamics. Leading organizations are responding with advanced platforms, strategic partnerships, and AI-enabled capabilities, setting new benchmarks for safety surveillance.

Looking ahead, the imperative for harmonized data ecosystems, proactive risk management, and continuous technological adoption will define competitive advantage. This executive summary provides a strategic road map for stakeholders seeking to strengthen pharmacovigilance operations, optimize resource allocation, and uphold the highest standards of patient safety.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Type
    • Cohort Event Monitoring
    • EHR Mining
    • Intensified ADR Reporting
    • Spontaneous Reporting
    • Targeted Spontaneous Reporting
  • Product Life Cycle
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
    • Pre-clinical
  • Delivery Mode
    • In-house
    • Outsourced
  • Process Flow
    • Case Data Management
      • Case Data Analysis
      • Case Logging
      • Medical Reviewing & Reporting
    • Risk Management System
      • Risk Evaluation System
      • Risk Mitigation System
    • Signal Detection
      • Adverse Event Analysis
      • Adverse Event Logging
      • Adverse Event Review & Reporting
  • Therapeutic Area
    • Cardiovascular
    • Infectious Diseases
    • Neurology
    • Oncology
    • Respiratory
  • End-user
    • Biotechnology Companies
    • Medical Device Manufacturers
    • Pharmaceuticals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi S.A.
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pharmacovigilance Market, by Type
8.1. Introduction
8.2. Cohort Event Monitoring
8.3. EHR Mining
8.4. Intensified ADR Reporting
8.5. Spontaneous Reporting
8.6. Targeted Spontaneous Reporting
9. Pharmacovigilance Market, by Product Life Cycle
9.1. Introduction
9.2. Phase I
9.3. Phase II
9.4. Phase III
9.5. Phase IV
9.6. Pre-clinical
10. Pharmacovigilance Market, by Delivery Mode
10.1. Introduction
10.2. In-house
10.3. Outsourced
11. Pharmacovigilance Market, by Process Flow
11.1. Introduction
11.2. Case Data Management
11.2.1. Case Data Analysis
11.2.2. Case Logging
11.2.3. Medical Reviewing & Reporting
11.3. Risk Management System
11.3.1. Risk Evaluation System
11.3.2. Risk Mitigation System
11.4. Signal Detection
11.4.1. Adverse Event Analysis
11.4.2. Adverse Event Logging
11.4.3. Adverse Event Review & Reporting
12. Pharmacovigilance Market, by Therapeutic Area
12.1. Introduction
12.2. Cardiovascular
12.3. Infectious Diseases
12.4. Neurology
12.5. Oncology
12.6. Respiratory
13. Pharmacovigilance Market, by End-user
13.1. Introduction
13.2. Biotechnology Companies
13.3. Medical Device Manufacturers
13.4. Pharmaceuticals
14. Americas Pharmacovigilance Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Pharmacovigilance Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Pharmacovigilance Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Accenture, PLC
17.3.2. Bristol-Myers Squibb Company
17.3.3. Capgemini SE
17.3.4. ClinChoice
17.3.5. F. Hoffmann-La Roche AG
17.3.6. GlaxoSmithKline PLC
17.3.7. HCL Technologies Limited
17.3.8. ICON PLC
17.3.9. Infosys Limited
17.3.10. International Business Machines Corporation
17.3.11. IQVIA Inc.
17.3.12. ITclinical
17.3.13. Laboratory Corporation of America Holdings
17.3.14. Linical Co., Ltd.
17.3.15. Novartis AG
17.3.16. Oracle Corporation
17.3.17. Parexel International
17.3.18. Pfizer Inc.
17.3.19. Quanticate International limited
17.3.20. Sanofi S.A.
17.3.21. Syneos Health
17.3.22. TAKE Solutions Limited
17.3.23. TATA Consultancy Services Limited
17.3.24. Wipro Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PHARMACOVIGILANCE MARKET MULTI-CURRENCY
FIGURE 2. PHARMACOVIGILANCE MARKET MULTI-LANGUAGE
FIGURE 3. PHARMACOVIGILANCE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY OUTSOURCED, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE LOGGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL REVIEWING & REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK EVALUATION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MITIGATION SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT LOGGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ADVERSE EVENT REVIEW & REPORTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY MEDICAL DEVICE MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 66. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 68. CANADA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 69. CANADA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 70. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 71. CANADA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 72. CANADA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 73. CANADA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 74. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 78. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 79. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 80. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 81. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 82. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 83. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 120. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 125. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 126. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 127. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 128. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 129. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 131. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 132. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 133. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 134. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 135. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 136. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 137. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 138. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 146. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 147. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 149. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 150. ITALY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 151. ITALY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 152. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 153. ITALY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 154. ITALY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 155. ITALY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 156. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 158. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 159. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 160. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 161. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 162. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 163. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 164. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 165. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 173. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 174. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 191. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 192. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 194. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 195. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 196. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 197. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 198. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 199. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 200. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 201. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 209. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 212. QATAR PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 213. QATAR PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 214. QATAR PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 215. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 216. QATAR PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 217. QATAR PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 218. QATAR PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 219. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 222. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 223. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 224. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 225. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 226. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 227. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 228. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 236. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 237. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 246. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 248. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 249. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 250. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 251. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 252. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 253. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 254. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 255. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 257. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 258. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 259. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 260. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 261. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 262. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 263. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 264. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 276. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 277. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 278. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 279. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 280. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 281. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 282. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 283. POLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 284. POLAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 285. POLAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 286. POLAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 287. POLAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 288. POLAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 289. POLAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 290. POLAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 291. POLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 299. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 300. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 309. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 310. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 311. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 312. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 313. CHINA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 314. CHINA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 315. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 316. CHINA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 317. CHINA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 318. CHINA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 319. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 320. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 321. INDIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 322. INDIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 323. INDIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 324. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 325. INDIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 326. INDIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 327. INDIA PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 328. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 329. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 330. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 331. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 332. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 333. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 334. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 335. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 336. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 337. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 338. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 339. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY PRODUCT LIFE CYCLE, 2018-2030 (USD MILLION)
TABLE 340. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY DELIVERY MODE, 2018-2030 (USD MILLION)
TABLE 341. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY PROCESS FLOW, 2018-2030 (USD MILLION)
TABLE 342. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY CASE DATA MANAGEMENT, 2018-2030 (USD MILLION)
TABLE 343. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY RISK MANAGEMENT SYSTEM, 2018-2030 (USD MILLION)
TABLE 344. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY SIGNAL DETECTION, 2018-2030 (USD MILLION)
TABLE 345. AUSTRALIA P

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pharmacovigilance market report include:
  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi S.A.
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited

Table Information

Report AttributeDetails
No. of Pages185
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.84 Billion
Forecasted Market Value ( USD ) by 2030 $ 24.76 Billion
Compound Annual Growth Rate15.8%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Pharmacovigilance & Drug Safety Software Market by Component, Deployment Mode, End User, Application, Organization Size - Global Forecast to 2030 - Product Image

Pharmacovigilance & Drug Safety Software Market by Component, Deployment Mode, End User, Application, Organization Size - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2024-2032 - Product Image

Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2025-2033 - Product Image

Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2025-2033

  • Report
  • 134 Pages
  • Global
From
Post-Marketing Pharmacovigilance and Medical Information - Global Strategic Business Report - Product Image

Post-Marketing Pharmacovigilance and Medical Information - Global Strategic Business Report

  • Report
  • 285 Pages
  • Global
From

About the Pharmacovigilance Market

The Pharmacovigilance market is a subset of the Healthcare Services industry, focusing on the monitoring and assessment of the safety of pharmaceutical products. It involves the collection, analysis, and reporting of adverse events related to the use of drugs, as well as the identification of potential risks associated with their use. Pharmacovigilance activities are conducted by pharmaceutical companies, regulatory authorities, and healthcare professionals. Pharmacovigilance activities are essential for the safe and effective use of drugs, as they help to identify potential risks and ensure that the benefits of the drug outweigh the risks. Pharmacovigilance also helps to ensure that the drug is used appropriately and that any adverse events are reported and addressed. Some companies in the Pharmacovigilance market include Parexel, Quintiles, Covance, PRA Health Sciences, and ICON. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.